Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease

@article{Kulisevsky2010TolerabilityAS,
  title={Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson’s Disease},
  author={Jaime Kulisevsky and Javier Pagonabarraga},
  journal={Drug Safety},
  year={2010},
  volume={33},
  pages={147-161}
}
Background: Dopamine agonists have a well established role in the treatment of Parkinson’s disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.Objective: The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (bromocriptine, cabergoline, pramipexole, rotigotine, pergolide) and placebo in monotherapy and adjuvant therapy with levodopa in the treatment of Parkinson’s… 
Drug safety evaluation of ropinirole prolonged release
TLDR
RPR was generally well tolerated in both early and advanced Parkinsonian patients and has also demonstrated to be effective in ameliorating the quality of sleep without increasing the occurrence of daily sleepiness and nocturnal psychosis.
A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease
TLDR
Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson’s disease and by now dopamine agonists treatment should be tailored on specific adverse events profile.
Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
TLDR
The results showed that ropinirole does not influence LD or 3-OMD concentrations, and higher 3- OMD levels play a role in inducing motor complications during long-term levodopa therapy.
The effect and safety of ropinirole in the treatment of Parkinson disease
TLDR
Ropinirole can help improve the ability of daily living and exercise function of PD patients, but it will increase the incidence of related adverse reactions, which needs to be further confirmed by subsequent large-scale, high-quality RCTs.
Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease
TLDR
The focus of this review is the side-effect and safety profiles of carbidopa/levodopa, dopamine agonists, selective monoamine oxidase inhibitor, catechol-o-methyltransferase inhibitors, anticholinergics and amantadine.
Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
  • J. Borovac
  • Medicine, Biology
    The Yale journal of biology and medicine
  • 2016
TLDR
The goal of this review is to provide a comprehensive, up-to-date overview of DA therapeutic modalities for PD.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease
TLDR
Ropinirole as an adjunct to Levodopa in the treatment of PD with motor fluctuation was associated with more significant reduction of levodopa dose and, on one form of analysis, with significantly greater improvement in CGI ratings than bromocriptine.
Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
  • M. Kuzel
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 1999
TLDR
In patients with early PD, initial monotherapy with ropinirole was more effective than placebo or bromocriptine in the absence of selegiline and was as effective as bromodopa in the presence of seLegiline.
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
TLDR
It is indicated that pramipexole is safe and effective in the treatment of early Parkinson's disease and significantly reduced the severity of PD symptoms and signs compared with placebo.
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
TLDR
Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations and delays the possibility of adverse effect onset.
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
TLDR
Rpinirole is a safe and well-tolerated drug and, as monotherapy, provided significant therapeutic benefit compared with placebo to patients in the early stages of Parkinson's disease.
Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson’s Disease
TLDR
Use of ropinirole seems to be associated with a higher risk of hypotension and somnolence than use of pramipexole when compared with placebo, and use of pramipexoles seems to been associated with an higher risk with hallucinations than use with placebo.
Pergolide monotherapy in the treatment of early PD
TLDR
This study suggests that pergolide monotherapy may be an efficacious and well-tolerated first-line treatment in patients with early-stage PD.
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
TLDR
It is concluded that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points and in regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups, there was a trend to significance in favor of pramipingxole.
Comparative Tolerability of the Newer Generation Antiparkinsonian Agents
TLDR
The newer, non-ergoline dopamine agonists, pramipexole and ropinirole, have undergone extensive studies to evaluate their efficacy as monotherapy in early Parkinson’s disease, and seem to be comparable to that of the older agents, bromocriptine and pergolide.
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study
TLDR
Pramipexole administration is an efficacious and well tolerated add on therapy in patients with advanced Parkinson’s disease with an improvement in activities of daily living, motor function, and treatment associated complications.
...
...